A fully independent clinical trial researchers thought might disprove a cardiac device made by Shockwave Medical, the company that Johnson & Johnson is buying for $13 billion, ended up providing some support for the device’s utility.
The data, presented Monday at the annual meeting of the American College of Cardiology and published in The Lancet, could bolster the case for the device, which is available in Europe and the U.K. but was previously rejected by the U.S. Food and Drug Administration.
But the results are also complicated, because, technically, though the study does show that the device reduced angina, the chest pain caused by heart disease, it also failed.
The device, called a coronary sinus reducer, is meant to reduce chest pain by forcing blood backward through the heart’s veins. The primary goal of the small trial was to use magnetic resonance imaging to see if this happened.
Click this link for the original source of this article.
Author: Lizzy Lawrence and Matthew Herper
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.